Bank of New York Mellon Corp Acquires 725,536 Shares of Ocugen, Inc. (NASDAQ:OCGN)

Bank of New York Mellon Corp grew its stake in Ocugen, Inc. (NASDAQ:OCGN) by 2,760.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 751,819 shares of the company’s stock after buying an additional 725,536 shares during the period. Bank of New York Mellon Corp owned approximately 0.29% of Ocugen worth $1,165,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in OCGN. State Board of Administration of Florida Retirement System bought a new position in shares of Ocugen in the 1st quarter valued at approximately $132,000. Tidal Investments LLC bought a new position in shares of Ocugen in the first quarter valued at approximately $108,000. Headlands Technologies LLC acquired a new stake in shares of Ocugen in the first quarter worth $66,000. Baader Bank Aktiengesellschaft bought a new stake in shares of Ocugen during the 2nd quarter worth $35,000. Finally, David J Yvars Group acquired a new position in Ocugen in the 1st quarter valued at $35,000. Institutional investors own 10.27% of the company’s stock.

Ocugen Stock Performance

Shares of OCGN opened at $1.11 on Friday. The company has a market capitalization of $285.66 million, a PE ratio of -4.44 and a beta of 3.69. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.04 and a quick ratio of 1.04. Ocugen, Inc. has a one year low of $0.35 and a one year high of $2.11. The company’s fifty day moving average price is $1.35 and its 200 day moving average price is $1.46.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $1.14 million during the quarter. During the same quarter in the previous year, the firm earned ($0.10) EPS. As a group, analysts expect that Ocugen, Inc. will post -0.2 earnings per share for the current year.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.